Works matching DE "ERLOTINIB"
Results: 1003
The War on Pancreatic Cancer: We Are Not There Yet.
- Published in:
- 2014
- By:
- Publication type:
- Opinion
Treatment of Metastatic Pancreatic Adenocarcinoma: New Options and Promising Strategies.
- Published in:
- 2014
- By:
- Publication type:
- Opinion
Treatment of Metastatic Pancreatic Adenocarcinoma: A Review.
- Published in:
- Oncology (08909091), 2014, v. 28, n. 1, p. 70
- By:
- Publication type:
- Article
Expanding Options for Pancreatic Cancer... So Where Do We Go From Here?
- Published in:
- Oncology (08909091), 2014, v. 28, n. 1, p. 5
- By:
- Publication type:
- Article
Tumor Inhibition Achieved by Targeting and Regulating Multiple Key Elements in EGFR Signaling Pathway Using a Self‐Assembled Nanoprodrug.
- Published in:
- Advanced Functional Materials, 2018, v. 28, n. 22, p. 1, doi. 10.1002/adfm.201800692
- By:
- Publication type:
- Article
Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non–small cell lung cancer (NSCLC) with brain metastases.
- Published in:
- European Journal of Clinical Pharmacology, 2020, v. 76, n. 10, p. 1427, doi. 10.1007/s00228-020-02926-9
- By:
- Publication type:
- Article
Epithelial growth factor receptor tyrosine kinase inhibitors alleviate house dust mite allergen Der p2‐induced IL‐6 and IL‐8.
- Published in:
- Environmental Toxicology, 2019, v. 34, n. 4, p. 476, doi. 10.1002/tox.22701
- By:
- Publication type:
- Article
Epidermal growth factor receptor (EGFR)-MAPK-nuclear factor(NF)-κB-IL8: A possible mechanism of particulate matter(PM) 2.5-induced lung toxicity.
- Published in:
- Environmental Toxicology, 2017, v. 32, n. 5, p. 1628, doi. 10.1002/tox.22390
- By:
- Publication type:
- Article
Physicochemical characterisation and cyclodextrin complexation of erlotinib.
- Published in:
- Supramolecular Chemistry, 2016, v. 28, n. 7/8, p. 656, doi. 10.1080/10610278.2015.1117083
- By:
- Publication type:
- Article
Squamous cell carcinoma of the lung.
- Published in:
- Oncolog-Hematolog, 2016, n. 36, p. 42
- By:
- Publication type:
- Article
非小细胞肺癌 EGFR-TKIs 治疗及PET分子成像的研究进展.
- Published in:
- Progress in Modern Biomedicine, 2020, v. 20, n. 4, p. 793, doi. 10.13241/j.cnki.pmb.2020.04.042
- By:
- Publication type:
- Article
血清CEA、CA211 水平与晚期非小细胞肺癌靶向治疗患者疗效、预后的 关系及其诊断价值分析
- Published in:
- Progress in Modern Biomedicine, 2019, v. 19, n. 18, p. 3527, doi. 10.13241/j.cnki.pmb.2019.18.028
- By:
- Publication type:
- Article
丝氨酸生物合成途径介导肺腺癌细胞EGFR-TKIs 靶向治疗适应性耐药.
- Published in:
- Progress in Modern Biomedicine, 2019, v. 19, n. 17, p. 3218, doi. 10.13241/j.cnki.pmb.2019.17.004
- By:
- Publication type:
- Article
Long noncoding LUCAT1 promotes cisplatin resistance of non-small cell lung cancer by promoting IGF-2.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Design, Synthesis, In Vitro Anticancer and ADMET Studies of Piperazine-Pyrazolo-Quinoxalin-2(1H)-one Conjugate as EGFR Targeting Agents.
- Published in:
- Russian Journal of General Chemistry, 2025, v. 95, n. 1, p. 184, doi. 10.1134/S1070363224610366
- By:
- Publication type:
- Article
Design and Synthesis of New Quinoxaline-thiazolidine-2,4-dione-isoxazole Conjugates as EGFR Targeting Agents.
- Published in:
- Russian Journal of General Chemistry, 2024, v. 94, n. 7, p. 1738, doi. 10.1134/S107036322407017X
- By:
- Publication type:
- Article
Synthesis, Anti-Breast Cancer, and EGFR Activity of Novel Pyrido[2,3-d]pyrimidine-piperazine-1,2,4-oxadiazoles.
- Published in:
- Russian Journal of General Chemistry, 2024, v. 94, n. 6, p. 1464, doi. 10.1134/S1070363224060239
- By:
- Publication type:
- Article
One-Pot Synthesis of 6-Amino-4-(furan/thiophen/pyrrol-2-yl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitriles, Evaluation of Anticancer Activity and Molecular Modelling Studies.
- Published in:
- Russian Journal of General Chemistry, 2023, v. 93, n. 1, p. 128, doi. 10.1134/S1070363223010188
- By:
- Publication type:
- Article
Synthesis and Anticancer Activity of Some New 4-Azaindoleisoxazoles.
- Published in:
- Russian Journal of General Chemistry, 2022, v. 92, n. 3, p. 470, doi. 10.1134/S107036322203015X
- By:
- Publication type:
- Article
Synthesis and Biological Activity of 3,9-Diazatetraasteranes as Novel EGFR Tyrosine Kinase Inhibitors.
- Published in:
- Russian Journal of General Chemistry, 2022, v. 92, n. 3, p. 446, doi. 10.1134/S1070363222030124
- By:
- Publication type:
- Article
The Effect of Single-Dose Ougan Juice Application on the Pharmacokinetics of Erlotinib.
- Published in:
- BioMed Research International, 2021, p. 1, doi. 10.1155/2021/6679082
- By:
- Publication type:
- Article
Erlotinib Improves the Response of Glioblastoma Cells Resistant to Photodynamic Therapy.
- Published in:
- Brain Sciences (2076-3425), 2024, v. 14, n. 12, p. 1192, doi. 10.3390/brainsci14121192
- By:
- Publication type:
- Article
Integrated analysis of EGFR mutated non‐small cell lung cancer reveals two distinct molecular subtypes.
- Published in:
- Clinical & Translational Medicine, 2023, v. 13, n. 10, p. 1, doi. 10.1002/ctm2.1431
- By:
- Publication type:
- Article
APE1 shRNA‐loaded cancer stem cell‐derived extracellular vesicles reverse Erlotinib resistance in non‐small cell lung cancer via the IL‐6/STAT3 signalling.
- Published in:
- Clinical & Translational Medicine, 2022, v. 12, n. 5, p. 1, doi. 10.1002/ctm2.876
- By:
- Publication type:
- Article
Matrix‐assisted laser desorption ionization ‐ mass spectrometry imaging of erlotinib reveals a limited tumor tissue distribution in a non‐small‐cell lung cancer mouse xenograft model.
- Published in:
- Clinical & Translational Medicine, 2021, v. 11, n. 7, p. 1, doi. 10.1002/ctm2.481
- By:
- Publication type:
- Article
Efficacy of erlotinib and its effects on the quality of life of older patients with epidermal growth factor receptor‐mutant non‐small cell lung cancer: A prospective, multicenter, dose‐modification study.
- Published in:
- Geriatrics & Gerontology International, 2021, v. 21, n. 10, p. 881, doi. 10.1111/ggi.14243
- By:
- Publication type:
- Article
Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2015, v. 40, n. 6, p. 661, doi. 10.1111/jcpt.12332
- By:
- Publication type:
- Article
A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2015, v. 40, n. 4, p. 391, doi. 10.1111/jcpt.12273
- By:
- Publication type:
- Article
Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2015, v. 40, n. 2, p. 232, doi. 10.1111/jcpt.12232
- By:
- Publication type:
- Article
Effectiveness and safety of the bevacizumab and erlotinib combination versus erlotinib alone in EGFR mutant metastatic non-small-cell lung cancer: systematic review and meta-analysis.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2023.1335373
- By:
- Publication type:
- Article
The activity of a PI3K δ-sparing inhibitor, MEN1611, in non-small cell lung cancer cells with constitutive activation of the PI3K/AKT/mTOR pathway.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1283951
- By:
- Publication type:
- Article
Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2ndgeneration EGFR-tyrosine kinase inhibitors.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1249106
- By:
- Publication type:
- Article
Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1238883
- By:
- Publication type:
- Article
Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats.
- Published in:
- EJNMMI Research, 2018, v. 8, n. 1, p. 1, doi. 10.1186/s13550-018-0434-0
- By:
- Publication type:
- Article
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
- Published in:
- Lung Cancer: Targets & Therapy, 2017, v. 8, p. 109, doi. 10.2147/LCTT.S119644
- By:
- Publication type:
- Article
Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics.
- Published in:
- Lung Cancer: Targets & Therapy, 2014, v. 5, p. 73, doi. 10.2147/LCTT.S50671
- By:
- Publication type:
- Article
EGFR-Blockade With Erlotinib Reduces EGF and TGF-β2 Expression and the Actin-Cytoskeleton Which Influences Different Aspects of Cellular Migration in Lens Epithelial cells.
- Published in:
- Current Eye Research, 2014, v. 39, n. 10, p. 1000, doi. 10.3109/02713683.2014.888453
- By:
- Publication type:
- Article
A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma.
- Published in:
- International Journal of Cancer, 2022, v. 151, n. 9, p. 1565, doi. 10.1002/ijc.34144
- By:
- Publication type:
- Article
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first‐line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1).
- Published in:
- International Journal of Cancer, 2021, v. 148, n. 3, p. 682, doi. 10.1002/ijc.33225
- By:
- Publication type:
- Article
Radioresistance of KRAS/TP53‐mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo.
- Published in:
- International Journal of Cancer, 2020, v. 147, n. 2, p. 472, doi. 10.1002/ijc.32598
- By:
- Publication type:
- Article
Osimertinib confers potent binding affinity to EGFR kinase domain duplication.
- Published in:
- International Journal of Cancer, 2019, v. 145, n. 10, p. 2884, doi. 10.1002/ijc.32617
- By:
- Publication type:
- Article
From "Glivec®" to "Prevnar 13®": How strong is the Indian drug patenting system?
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
Cutaneous Side Effects During Therapy With Erlotinib - Case Report.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
In-silico DESIGN SCREENING OF SOME PYRAZOLONE FUSED HETEROCYCLIC ANALOGUES AS HER2 INHIBITORS TARGETING BREAST CANCER.
- Published in:
- Rasayan Journal of Chemistry, 2022, v. 15, n. 1, p. 497, doi. 10.31788/RJC.2022.1516738
- By:
- Publication type:
- Article
QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP (QSAR) OF N-BENZOYL-N'-PHENYLTHIOUREA COMPOUND AND DERIVATIVES IN MCF-7 CANCER CELLS.
- Published in:
- Rasayan Journal of Chemistry, 2021, v. 14, n. 4, p. 2698, doi. 10.31788/RJC.2021.1446357
- By:
- Publication type:
- Article
DEVELOPMENT AND VALIDATION OF A STABILITY-INDICATING RP-HPLC METHOD FOR THE ESTIMATION OF ERLOTINIB IMPURITIES BY QbD APPROACH.
- Published in:
- Rasayan Journal of Chemistry, 2016, v. 9, n. 2, p. 180
- By:
- Publication type:
- Article
Purchase of prophylactic topical corticosteroids is associated with improved survival in NSCLCs treated with EGFR TKI: real-world cohort study.
- Published in:
- Acta Oncologica, 2021, v. 60, n. 9, p. 1100, doi. 10.1080/0284186X.2021.1937309
- By:
- Publication type:
- Article
NAD(P)H Quinone Oxidoreductase-1 Expression Promotes Self-Renewal and Therapeutic Resistance in Non-Small Cell Lung Cancer.
- Published in:
- Genes, 2023, v. 14, n. 3, p. 607, doi. 10.3390/genes14030607
- By:
- Publication type:
- Article
Suppression of Epidermal Growth Factor Receptor by Erlotinib Attenuates Carvacrol-induced Skin Inflammation.
- Published in:
- Acta Dermato-Venereologica, 2024, v. 104, p. 1, doi. 10.2340/actadv.v104.40975
- By:
- Publication type:
- Article
Comparative of in-vitro Evaluation between Erlotinib Loaded Nanostructured Lipid Carriers and Liposomes against A549 Lung Cancer Cell Line.
- Published in:
- Iranian Journal of Pharmaceutical Research, 2019, v. 18, n. 3, p. 1168, doi. 10.22037/ijpr.2019.1100775
- By:
- Publication type:
- Article